Medication info

Grid Tablet (Glimepiride)

Prescription medicationExpired
Ingredient · strength
Glimepiride›Strength being verified
Manufacturer / importer
Future Bio Pharmaceutical Co., Ltd.
Appearance
Green rectangular tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Expired

MFDS item code 201307112 · Approved 2013.04.29

This product's status changed to Expired on 2023.04.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
Adjust individually for each patient. Swallow without chewing with at least 1/2 glass of water. Administer this drug orally once daily. Take this drug before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this drug. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received medication, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional effect at doses above 4 mg, although some patients achieved better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the patient's need for this drug may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral antihyperglycemic agent to this drug There is no exact dose equivalence between this drug and other oral antihyperglycemic agents. When switching from another oral antihyperglycemic agent to this drug, it is recommended to follow the method described under Initial dose. That is, start with 1 mg once daily and adjust the dose at intervals of 1 ~ 2 weeks. Consider the potency and duration of action of the previously administered drug. 4) Dose adjustment during treatment While taking this drug, blood glucose and/or urine glucose levels should be measured regularly; regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Hypoglycemia may recur after successful initial management during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this drug and insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this drug once daily with the first meal. Start insulin at a low dose and increase it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin dosage should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, the addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to identify the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this drug is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Ingredients

Manufacturer
Future Bio Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used in conjunction with dietary and exercise therapies to help patients with Type 2 diabetes regulate their blood sugar levels. It can be administered alone or in combination with other hypoglycemic agents or insulin if blood sugar control is inadequate. Particularly, when oral sulfonylureas or metformin monotherapy is insufficiently effective, it is used alongside metformin to improve blood sugar control. It assists in blood sugar management in various ways, contributing to the maintenance of a healthy life.

Dosage and Administration

Adult dosage

Adjust individually for each patient. Swallow without chewing with at least 1/2 glass of water. Administer this drug orally once daily. Take this drug before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this drug. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received medication, initiate treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional effect at doses above 4 mg, although some patients achieved better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg once daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic drug. 2) Subsequent dose adjustment As diabetes control improves during treatment, the patient's need for this drug may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered if weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia occur. 3) Switching from another oral antihyperglycemic agent to this drug There is no exact dose equivalence between this drug and other oral antihyperglycemic agents. When switching from another oral antihyperglycemic agent to this drug, it is recommended to follow the method described under Initial dose. That is, start with 1 mg once daily and adjust the dose at intervals of 1 ~ 2 weeks. Consider the potency and duration of action of the previously administered drug. 4) Dose adjustment during treatment While taking this drug, blood glucose and/or urine glucose levels should be measured regularly; regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Hypoglycemia may recur after successful initial management during treatment with sulfonylureas. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this drug and insulin is used in patients with secondary failure, and is used when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this drug once daily with the first meal. Start insulin at a low dose and increase it approximately weekly according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. Insulin dosage should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this drug, the addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this drug is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each drug. However, efforts should be made to identify the minimum effective dose of each drug for blood glucose control. There is a risk of hypoglycemia when this drug is administered with metformin, and the risk may increase. Appropriate precautions should be taken.

Precautions

This medication should not be used in patients with insulin-dependent diabetes mellitus, diabetic ketoacidosis, or in a comatose state. Additionally, it is not administered to patients who have had allergic reactions to this medication or its components, or those with severe liver or kidney dysfunction. It is also safer not to take this medication during pregnancy or breastfeeding. Patients who have severe infections, are undergoing surgery, or have severe trauma may require insulin treatment, so caution is necessary. Gastrointestinal disturbances such as diarrhea or vomiting can affect drug absorption, increasing the risk of hypoglycemia. Patients with inherited lactose metabolism disorders should not take this medication. During the first week of taking this medication, the risk of hypoglycemia is high, so blood sugar levels should be carefully monitored. Special caution is needed for the elderly, those with poor nutritional status, those with irregular eating habits, those where muscle activity and carbohydrate intake do not match, those with changes in eating patterns, those who frequently consume alcohol, and those with declining liver or kidney functions. Furthermore, the risk of hypoglycemia may also increase in patients with other endocrine disorders or those who have taken an overdose of medications. If symptoms of hypoglycemia occur during the use of this medication, the patient must immediately inform their doctor or pharmacist, and if necessary, the medication dose or administration method should be adjusted. This medication can cause hypoglycemia due to its blood sugar-lowering properties. Symptoms of hypoglycemia may include headache, severe hunger, nausea, vomiting, fatigue, anxiety, confusion, blurred vision, dizziness, drowsiness, and decreased consciousness. Severe hypoglycemia may lead to brain convulsions or coma, so caution is advised. Additionally, transient visual disturbances, gastrointestinal symptoms, liver function abnormalities, blood abnormalities, and allergic reactions may occur. If serious allergic symptoms such as hives or breathing difficulties develop, immediate medical treatment is necessary. When taking this medication, regular meals and exercise, as well as weight control if necessary, should be conducted, and if hypoglycemia occurs, quickly consuming sugar or sugary drinks can help adjust blood sugar levels. It is important to thoroughly inform patients and their families about methods of preventing and treating hypoglycemia. Furthermore, during stress situations, surgery, or infections where blood sugar control may be difficult, transition to insulin treatment may be necessary. This medication can interact with other drugs, affecting blood sugar control; thus, it is essential to inform the doctor or pharmacist when beginning or discontinuing other medications. Special caution is required when taken with drugs metabolized by the liver, and close monitoring of blood sugar changes should be conducted when combined with various medications that lower or raise blood sugar.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disturbances, anxiety, aggression, decreased concentration, decreased agility or activity, depression, confusion, speech disturbances, aphasia, visual disturbances, tremors, incomplete paralysis, sensory disturbances, dizziness, weakness, loss of self-control, transient mental confusion, seizures, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and moist skin, tachycardia, hypertension, palpitations, angina, deep vein thrombosis, blurred vision, fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased liver enzymes, liver dysfunction, bile secretion disorder, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, neutropenia, agranulocytosis, pancytopenia, itching, hives, rash, difficulty breathing, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, phototoxic reactions of the skin, decreased serum sodium concentration, altered taste, hair loss, weight gain, dizziness, liver dysfunction, abdominal pain, arthralgia, dyspepsia, facial swelling, erectile dysfunction, flushing of the face, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. It is advisable to keep it at a cool room temperature, between 1 degree and 30 degrees Celsius. This proper storage will help maintain the efficacy of the medication for a longer period.

Appearance and packaging

Appearance

Green rectangular tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.